228
Participants
Start Date
February 9, 2018
Primary Completion Date
December 24, 2018
Study Completion Date
March 31, 2022
BCD-085
120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
placebo
2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
"Non-governmental Healthcare Institution Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways", Chelyabinsk
Chelyabinsk Regional Clinical hospital, Chelyabinsk
Kazan State Medical University, Kazan'
State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University, Moscow
Omsk Regional Clinical Hospital, Omsk
LLC BioEk, Saint Petersburg
North-Western State Medical University n.a. I.I.Mechnikov, Saint Petersburg
Lead Sponsor
Biocad
INDUSTRY